PMID- 31387183
OWN - NLM
STAT- MEDLINE
DCOM- 20200117
LR  - 20200117
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 117
DP  - 2019 Sep
TI  - LMX1B mRNA expression and its gene body CpG methylation are valuable prognostic 
      biomarkers for laryngeal squamous cell carcinoma.
PG  - 109174
LID - S0753-3322(19)32028-1 [pii]
LID - 10.1016/j.biopha.2019.109174 [doi]
AB  - This study aimed to explore the prognostic value of LMX1B mRNA expression and the 
      methylation of its CpG sites in patients with laryngeal squamous cell carcinoma 
      (LSCC). An in-silicon analysis was performed using data from the cancer genome 
      atlas (TCGA)-Head and Neck Squamous Carcinoma (HNSC). After screening, 112 LSCC 
      and 10 adjacent normal tissues were identified as eligible samples for analysis. 
      Results showed that LMX1B expression was significantly upregulated in the cancer 
      tissues (p < 0.01) and was an independent prognostic indicator in terms of OS 
      (HR: 1.233, 95%CI: 1.082-1.405, p = 0.002) and RFS (HR: 1.200, 95%CI: 
      1.002-1.438, p = 0.048). By examining the methylation profile of 55 CpG sites in 
      LMX1B locus, we found that the promoter methylation status was irrelevant to 
      LMX1B expression. In comparison, LMX1B expression was generally positively 
      correlated with gene body methylation. Among the gene body CpG sites, cg13600622 
      methylation showed a better predictive value than LMX1B expression in terms of OS 
      (HR: 12.363, 95%CI: 1.076-142.033, p = 0.043), while cg14204784 methylation was a 
      better marker of shorter RFS (HR: 12.363, 95%CI: 1.076-142.033, p = 0.043). Among 
      the known downstream genes of LMX1B, only NR4A2 expression showed a moderately 
      negative correlation (Pearson's r = -0.54) with it in LSCC tissues. However, this 
      correlation was inconsistent with previous publications those reported a positive 
      correlation between them. Based on these findings, we infer that upregulated 
      LMX1B mRNA expression had an independent prognostic value in LSCC patients. 
      Increased gene body methylation might be an important mechanism of its 
      upregulation. Among the gene body CpG sites, cg13600622 and cg14204784 
      methylation level might be better prognostic markers than LMX1B mRNA expression 
      in terms of OS and RFS respectively.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Fan, Liang
AU  - Fan L
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Jingmen No. 1 People's 
      Hospital, 44800, Hubei, China.
FAU - Zhang, Aiping
AU  - Zhang A
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Jingmen No. 1 People's 
      Hospital, 44800, Hubei, China.
FAU - Deng, Pingping
AU  - Deng P
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Jingmen No. 1 People's 
      Hospital, 44800, Hubei, China. Electronic address: 1520257753@qq.com.
LA  - eng
PT  - Journal Article
DEP - 20190708
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (LIM homeobox transcription factor 1 beta)
RN  - 0 (LIM-Homeodomain Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinoma, Squamous Cell/*genetics/pathology
MH  - CpG Islands/*genetics
MH  - DNA Methylation/*genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Head and Neck Neoplasms/pathology
MH  - Humans
MH  - LIM-Homeodomain Proteins/*genetics
MH  - Laryngeal Neoplasms/*genetics/pathology
MH  - Male
MH  - Prognosis
MH  - Promoter Regions, Genetic/genetics
MH  - RNA, Messenger/*genetics
MH  - Squamous Cell Carcinoma of Head and Neck/genetics/pathology
MH  - Transcription Factors/*genetics
MH  - Up-Regulation/genetics
OTO - NOTNLM
OT  - LMX1B
OT  - Laryngeal squamous cell carcinoma
OT  - Methylation
OT  - Prognosis
EDAT- 2019/08/08 06:00
MHDA- 2020/01/18 06:00
CRDT- 2019/08/08 06:00
PHST- 2019/05/02 00:00 [received]
PHST- 2019/06/15 00:00 [revised]
PHST- 2019/06/25 00:00 [accepted]
PHST- 2019/08/08 06:00 [entrez]
PHST- 2019/08/08 06:00 [pubmed]
PHST- 2020/01/18 06:00 [medline]
AID - S0753-3322(19)32028-1 [pii]
AID - 10.1016/j.biopha.2019.109174 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2019 Sep;117:109174. doi: 10.1016/j.biopha.2019.109174. Epub 
      2019 Jul 8.